Kinox

Nitric oxide, the active ingredient in Kinox, is a vasodilator presented as a medical gas for endotracheopulmonary (inhalation) use. It selectively relaxes pulmonary vascular smooth muscle, providing targeted pulmonary vasodilation in patients with conditions such as persistent pulmonary hypertension of the newborn, acute respiratory distress syndrome, or postoperative pulmonary hypertension.

GNH USA supplies Kinox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The product complies with EU regulatory standards and is intended for use under specialist medical supervision.

Kinox (inhaled nitric oxide) is used as a selective pulmonary vasodilator in several clinical settings.

- Persistent pulmonary hypertension of the newborn (PPHN): reduces pulmonary arterial pressure and improves oxygenation. - Acute respiratory distress syndrome (ARDS): provides temporary improvement in oxygenation and ventilation. - Post‑cardiac surgery pulmonary hypertension: lowers right‑ventricular afterload and supports hemodynamics. - Right‑ventricular failure associated with elevated pulmonary pressures: enhances right‑ventricular performance by decreasing pulmonary vascular resistance.

Inhaled nitric oxide can produce a range of adverse reactions, most of which are related to its vasodilatory and oxidative properties.

Common Side Effects: - Methemoglobinemia: oxidation of hemoglobin reducing oxygen‑carrying capacity. - Nitrogen dioxide formation: irritant gas that can damage lung tissue. - Transient systemic hypotension: mild drop in systemic blood pressure. - Rebound pulmonary hypertension: increase in pulmonary pressure after abrupt discontinuation. - Increased intracranial pressure: especially in neonates.

Serious or Rare Side Effects: - Severe hypotension leading to organ hypoperfusion. - Platelet dysfunction and bleeding tendencies. - Pulmonary edema from fluid shifts. - Acute kidney injury secondary to hemodynamic changes. - Allergic reactions to the gas delivery system.

When using Kinox, clinicians should observe several safety measures to minimize risk.

- Dose titration: adjust concentration based on continuous hemodynamic and oxygenation monitoring. - Methemoglobin monitoring: regularly check levels to detect early methemoglobinemia. - NO2 monitoring: ensure nitrogen dioxide concentrations remain below safety thresholds. - Gradual weaning: taper the gas to avoid rebound pulmonary hypertension. - Contraindications: avoid in patients with known hypersensitivity to nitric oxide or its delivery components. - Store at ambient temperature below 25°C: keep cylinders upright, protect from heat, moisture and direct sunlight.

Inhaled nitric oxide may interact with other agents that affect vascular tone or hemoglobin.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of excessive systemic hypotension. - Methylene blue (used for methemoglobinemia): can antagonize nitric oxide effects. - Other potent vasodilators: may cause profound hypotension.

Moderate Interactions (Monitor Closely): - Inhaled anesthetics (e.g., sevoflurane): may potentiate vasodilatory response. - Nitric oxide donors (e.g., nitroglycerin): additive effects on blood pressure. - High oxygen concentrations: increase formation of nitrogen dioxide. - Anticoagulants: monitor for enhanced bleeding risk.